Global problem of drug-induced hearing loss

Annals of the New York Academy of Sciences

Volumn 884, Issue , 1999, Pages 1-14

  Arslan, Edoardo ^a,b   Orzan, Eva ^a   Santarelli, Rosamaria ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; CARBOPLATIN; CISPLATIN; ETACRYNIC ACID; FUROSEMIDE; LOOP DIURETIC AGENT; MACROLIDE; QUININE; SALICYLIC ACID;

CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG COST; DRUG DOSAGE FORM; FAMILY; HEARING; HEARING AID; HEARING LOSS; HUMAN; INFORMED CONSENT; INTRAVENOUS DRUG ADMINISTRATION; LIFE EXPECTANCY; OTOTOXICITY; PATIENT MONITORING; PRESCRIPTION; QUALITY OF LIFE; RISK; RISK BENEFIT ANALYSIS; VESTIBULAR SYSTEM;

EID: 0032786482     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb00277.x     Document Type: Conference Paper

References (71)

1. 1. American Speech Language Hearing Association. 1994. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36 (Suppl. 12): 11-19.
2. 2. Baker, S. R. & R. Wheeler. 1984. Intraarterial chemotherapy for head and neck cancer. Part 2: Clinical experience. Head Neck Surg. 6: 751-760.
3. 3. Barron, S. E. & E. A. Daigneault. 1987. Effect of cisplatin on hair cell morphology and lateral wall Na, K-ATPase activity. Hear. Res. 26: 131-137.
4. 4. Berek, J. S., et al. 1997. Ovarian cancer. In Cancer Medicine, J. F. Holland, Ed.: 2289-2326. Williams & Wilkins. London.
5. 5. Black, F. O., et al. 1982. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 92: 1363-1368.
6. 6. Brummett, R. E., et al. 1981. Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamicin. J. Clin. Pharmacol. 21: 628-636.
7. 7. Brummett, R. E. & K. E. Fox. 1989. Aminoglycoside-induced hearing loss in humans. Antimicrob. Agents Chemother. 33: 797-800.
8. 8. Brummett, R. E., et al. 1992. Quantitative relationships of the interaction between sound and kanamicin. Arch. Otolaryngol. Head Neck Surg. 118: 498-500.
9. 9. Chiodo, A. A. & P. W. Alberti. 1994. Experimental, clinical and preventive aspects of ototoxicity. Eur. Arch. Otorhinolaryngol. 251: 375-392.
10. 10. Clayman, G. L., et al. 1997. Head and neck cancer. In Cancer Medicine, J. F. Holland, Ed.: 1645-1710. Williams & Wilkins. London.
11. 11. Colvin, M. 1997. Alkylating agents and platinum antitumor compounds. In Cancer Medicine, J.F. Holland, Ed.: 949-976. Williams & Wilkins. London.
12. 12. Conlon, B., et al. 1998. Attenuation of neomycin ototoxicity by iron chelation. Laryngoscope 108: 284-287.
13. 13. Conlon, B. & D. W Smith. 1998. Supplemental iron exacerbates aminoglycoside ototoxicity in vivo. Hear. Res. 115: 1-5.
14. 14. Crann, S. A. & J. Schacht. 1996. Activation of aminoglycoside antibiotics to cytotoxins. Audiol. Neurootol. 1: 80-85.
15. 15. De Groot, J. C. M. J., et al. 1990. Ultrastructural localization of gentamicin in the cochlea. Hear. Res. 50: 35-42.
16. 16. Enfors, P., et al. 1996. Protection of auditory neurons from aminoglycoside ototoxicity by neurotrophin-3. Nature Med. 2: 463-467.
17. 17. Fausti, S. A., et al. 1992. High frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J. Infect. Dis. 165: 1026-1032.
18. 18. Fausti, S. A., et al. 1994. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 15: 232-239.
19. 19. Fausti, S. A., et al. 1995. Reliability of auditory brainstem responses from sequenced high-frequency (>8 kHz) tonebursts. Audiology 34: 177-188.
20. 20. Fischel-Ghodsian, N., et al. 1997. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am. J. Otolaryngol. 18: 173-178.
21. 21. Flentje, M., et al. 1991. Additive effects of cisplatin and radiation in human rumor cells under oxic conditions. Radiother. Oncol. 24: 60-63.
22. 22. Follezou, J. Y., et al. 1989. Intra-arterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma 36: 349-352.
23. 23. Gardner, J. C., et al. 1997. Familial Streptomycin ototoxicity in South African family: a mytochondrial disorder. J. Med. Genet. 34: 904-906.
24. 24. Garetz, S. L. & J. S. Schacht. 1995. Ototoxicity: of mice and man. In Clinical Aspects of Hearing, T. R. Van De Water et al., Eds.: 116-154. Springer-Verlag. New York.
25. 25. Gorga, M. P., et al. 1997. From laboratory to clinic: a large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss. Ear Hear. 18: 440-455.
26. 26. Guthrie, T. M. & L. Gynther. 1985. Acute deafness. A complication of high dose cisplatin. Arch. Otolaryngol. 111: 344-345.
27. 27. Hashino, E. & R. J. Salvi. 1996. Regenerated hair cells exhibit a transient resistance to aminoglycoside toxicity. Brain Res. 720: 172-182.
28. 28. Hawkins, J. E. 1976. Drug ototoxicity. In Handbook of Sensory Physiology, Vol. 5, W. D. Keidel and W. D. Neff, Eds.: 707-748. Springer-Verlag. Berlin.
29. 29. Henry, K. R., et al. 1981. Increased ototoxicity in both young and old mice. Arch. Otolaryngol. 107: 92-95.
30. 30. Howell, S. B., et al. 1982. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97: 845-851.
31. 31. Howell, S. B. 1985. Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin. Oncol. 12: 17-24.
32. 32. Kantoff, P. W., et al. 1997. Bladder cancer. In Cancer Medicine, J. F. Holland, Ed.: 2105-2124. Williams & Wilkins. London.
33. 33. Kawashiro, N., et al. 1996. Delayed post-neonatal intensive care unit hearing disturbance. Int. J. Pediatr. Otolaryngol. 34: 35-43.
34. 34. Kimitsuki, T., et al. 1993. Cisplatin blocks mechano-electric transducer current in chick cochlear hair cells. Hear. Res. 71: 64-68.
35. 35. Kobayashi, H., et al. 1987. Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J. Othorinolaryngol. Related Spec. 49: 67-72.
36. 36. Kohn, S., et al. 1988. Cisplatin ototoxicity in guinea pigs with special reference to toxic effetcs in the stria vascularis. Laryngoscope 98: 865-871.
37. 37. Komiyara, S., 1989. Establishment of tumor cell lines from a patient with head and neck cancer and their different sensitivities to anti-cancer agents. Cancer 63: 675-682.
38. 38. Kopelmann, J., et al. 1988. Ototoxicity of high dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98: 858-864.
39. 39. Laurell, G. & U. Jungnelius. 1990. High dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100: 724-734.
40. 40. Lehane, D. E., et al. Intra-arterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug Delivery 1: 69.
41. 41. Levy, J., et al. 1984. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J. Pediatr. 105: 117-124.
42. 42. Liopis, B., et al. 1985. Thiotepa versus adiamycin versus cisplatinum in the intravescical prophylaxis of superficial bladder tumors. Eur. Urol. 11: 73.
43. 43. Loehrer, P., et al. 1994. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 12: 483-488.
44. 44. Mandell, G. L., et al. 1995. Principles and Practice of Infectious Diseases. Churchill Livingstone. New York.
45. 45. Markman, M., et al. 1985. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur. J. Cancer Clin. Oncol. 21: 1015-1022.
46. 46. McAlpine, D. & B. M. Johnstone. 1991. The ototoxic mechanism of cisplatin. Hear. Res. 47: 191-204.
47. 47. Minija, B. M. 1998. Aetiology of deafness among the children at the Buguruni school for the deaf in Dar es Salaam, Tanzania. Int. J. Pediatr. Otolaryngol. 42: 225-231.
48. 48. Monsell, E. M., et al. 1997. Non hereditary hearing loss. In Clinical Otology, G. B. Hughes and M. L. Pensak, Eds.: 289-312. Thieme. New York.
49. 49. Mukhopadhyay, S., et al. 1993. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. J. Antimicrob. Chemother. 31: 429-436.
50. 50. Mulheran, M. & C. Degg. 1997. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subject. Br. J. Audiol. 31: 5-9.
51. 51. Nakai, Y., et al. 1982. Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol. 93: 227-232.
52. 52. Neijt, J. P., et al. 1984. Randomized trial comparing two combination chemotherapy regimens (hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2: 594-600.
53. 53. Omura, G., et al. 1986. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian cancer. Cancer 57: 1725-1730.
54. 54. Oudesluys-Murphy, A. M., et al. 1996. Neonatal hearing screening. Eur. J. Pediatr. 155: 429-435.
55. 55. Pasic,T. R. & R. A. Dobie. 1991. Cis-Platinum ototoxicity in children. Laryngoscope 101: 985-991.
56. 56. Pirvola, U., et al. 1995. The site of action of neuronal acidic fibroblast growth factor is the organ of Corti of the rat cohlea. Proc. Natl. Acad. Sci. USA 92: 9269-9273.
57. 57. Priuska, E. A. & J. Schacht. 1995. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem. Pharmacol. 50: 1749-1752.
58. 58. Ramsey, B. W., et al. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328: 1740-1746.
59. 59. Raz., R., et al. 1995. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur. J. Microbiol. Infect. Dis. 14: 88-91.
60. 60. Saito, T., et al. 1991. Cisplatin blocks depolarization-induced calcium entry in isolated cochlear hair cells. Hear. Res. 56: 143-147.
61. 61. Snow, J. P., et al. 1986. Adjuvant chemotherapy: The EORTC trials. In Head and Neck Oncology, H. J. G. Bloom, Ed.: 83-92. Raven. New York.
62. 62. Sone, M., et al. 1998. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Hear. Res. 115: 217-223.
63. 63. Song, B. B. & J. Schacht. 1996. Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hear. Res. 94: 87-93.
64. 64. Staecker, H., et al. 1997. Transforming growth factor alpha treatment alters intracellular calcium levels in hair cells and protects them from ototoxic damage in vitro. Int. J. Dev. Neurosci. 15: 553-562.
65. 65. Steinkamp, G., et al. 1989. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr. Pulmonol. 6: 91-98.
66. 66. Stewart, D. J., et al. 1987. Combined intraarterial and systemic chemotherapy for intracerebral tumors. Neurosurgery 21: 207-214.
67. 67. Strauss, M., et al. 1983. Cisplatinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 93: 1554-1559.
68. 68. Takehisa, S. 1996. Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro. Acta Otolaryngol. (Stockh.): 561-565.
69. 69. Vogelzang, N., et al. 1993. Methotrexate, vinblastine, doxorubicin, and cisplatinum followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J. Urol. 149: 753-757.
70. 70. Weatherly, R. A., et al. 1991. Cis-Platinum ototoxicity in children. Laryngoscope 101: 917-923.
71. 71. Yamamoto, T., et al. 1994. Cisplatin blocks voltage-dependent calcium current in dissociated outer hair cells of guinea pig cochlea. Brain Res. 648: 296-298.